From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.
Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi
GtoPdb Disease Summaries
This section gives an overview of the disease, and where available shows the following:
- Synonyms: Shows known synonyms for the disease.
- Description: Gives a basic description/definition of the disease.
- Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
- Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
- Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.
More information can be found in the help pages.
✖| Disease ID: | 249 | |
| Name: | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi | |
| Associated with: | 1 target | |
| Synonyms |
| CLOVE syndrome |
| Description |
| CLOVE syndrome is caused by gain-of-function mutation of the PI3KA gene. |
| Database Links |
|
OMIM:
612918 Orphanet: ORPHA140944 |
Targets
GtoPdb Disease Summaries - Targets
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | |
| Drugs: | CLOVE syndrome patients treated with the PI3Kα-selective kinase inhibitor alpelisib achieve significant reduction in symptoms across a varied range of tissues that are affected by this disease. |
| Side effects: | Alpelisib treatment was not associated with any substantial side effects in the nineteen CLOVE syndrome patients that were given the drug. |
| Therapeutic use: | Alpelisib is not yet an approved drug (May 2019) so is being tested in this select patient cohort on compassionate grounds. |
| Comments: | Use of alpelisib to treat CLOVE syndrome and other PI3KA-related overgrowth spectrum (PROS) conditions is claimed in patent WO/2017/140828 |
| References: | 1-2 |
Ligands
GtoPdb Disease Summaries - Ligands
Click ligand name to view ligand summary page
- Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
- Immuno: Immuno icon indicates the ligand is immuno-relevant
Click the arrow in the final column to expand comments
- Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
- Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
- Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.
More information can be found in the help pages.
✖No ligand related data available for Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi
References
1. Canaud G. (2017) BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME). Patent number: WO2017140828. Assignee: INERM, CNRS, UNIVERSITÉ PARIS DESCARTES, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS. Priority date: 17/02/2017. Publication date: 24/08/2017.
2. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O et al.. (2018) Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 558 (7711): 540-546. [PMID:29899452]
